New weight drug VCT220 tested for drug interactions in healthy volunteers
NCT ID NCT07065058
First seen Mar 31, 2026 · Last updated May 25, 2026 · Updated 6 times
Summary
This study looked at how a new medicine called VCT220 interacts with three common drugs (repaglinide, rosuvastatin, and digoxin) in 24 healthy overweight adults. Participants took the drugs alone and then with VCT220 to measure changes in drug levels and safety. The goal was to gather information, not to treat obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Second University Hospital
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.